Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Ueno*1, Y. Murakami1, T. Iwama1, T. Sasaki1, T. Kunogi1, K. Takahashi1, K. Tanaka2, K. Ando1, S. Kashima1, Y. Inaba3, K. Moriichi1, H. Tanabe1, M. Taruishi3, M. Fujiya1, T. Okumura1

1Asahikawa Medical University, Department of Medicine, Asahikawa, Japan, 2Asahikawa Kosei General Hospital, Asahikawa, Japan, 3Asahikawa City Hospital, Asahikawa, Japan

P615: Rescue infliximab for acute severe colitis: a single-centre experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Orpen-Palmer*1, F. Clegg1,2, U. Basavaraju1, G. H. Bain1, C. N. Parnaby1, M. G. Smith1, M. H. McLean1,2, J. M. Thomson1

1Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK, 2University of Aberdeen, Aberdeen, UK

P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Rao*1, R. Gadhok1, L. Whitley2, N. Burgess1, P. Amon1, S. Naik1, J. Lindsay1, S. McCartney2, K. Kok1

1The Royal London Hospital, Gastroenterology, London, UK, 2University College London Hospital, Gastroenterology, London, UK

P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Costantino*1, G. Mandraffino1, S. Tomeo1, A. Sitibondo1, M. Scolaro1, C. Zito2, G. Di Bella2, S. Loddo3, W. Fries1

1AOU G. Martino – Messina, Department of Clinical and Experimental Medicine, IBD Unit, University of Messina, Messina, Italy, 2AOU G. Martino – Messina, Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy, 3AOU G. Martino - Messina, Department of Clinical and Experimental Medicine, Laboratory Medicine Unit, University of Messina, Messina, Italy

P618: Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Venturin1, S. Nancey1, X. Roblin2, L. Peyrin-Biroulet3, N. Mathieu4, B. Flourié1, G. Boschetti*1

1Lyon-Sud Hospital, Gastroenterology, Pierre Bénite, France, 2CHU Saint-Etienne, Gastroenterology, Saint-Etienne, France, 3CHU Nancy, Gastroenterology, Nancy, France, 4CHU Grenoble, Gastroenterology, Grenoble, France

P619: Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

ECCO '19 Copenhagen

Year: 2019
Authors:

D. T. Rubin1, S. Travis2, B. P. Abraham3, C. Su4, N. Lawendy4, H. Fan4, D. A. Woodworth4, A. J. Thorpe4, C. I. Nduaka4, D. Quirk4, W. Reinisch*5

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA, 2University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, Oxford, UK, 3Houston Methodist – Weill Cornell, Division of Gastroenterology and Hepatology, Houston, TX, USA, 4Pfizer Inc., Collegeville, PA, USA, 5Medical University of Vienna, Vienna, Austria

P620: Stapled end-to-side vs. side-to-side anastomosis after ileocecectomy for Crohn’s disease: a propensity score-matched analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Brandstetter1, M. Gouvea Monteiro de Camargo1, A. Aiello2, L. Stocchi1, J. M. Church1, T. Hull1, I. Lavery1, S. R. Steele1, S. Holubar*1, M. Valente1

1Cleveland Clinic Foundation, Colorectal Surgery, Cleveland, USA, 2Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA

P621: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Bressler*1, G. Mantzaris2, M. Silverberg3, P. Zezos3, D. Stein4, C. Colby5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, A. Yarur11

1St. Paul's Hospital, Vancouver, Canada, 2Evangelismos Hospital, Athens, Greece, 3IBD Center, Mount Sinai Hospital, Toronto, Canada, 4Evidera, London, UK, 5Evidera, California, USA, 6Takeda USA Inc., Chicago, USA, 7Takeda SA Inc., Athens, Greece, 8Takeda Canada Inc., Toronto, Canada, 9Takeda Pharmaceuticals International, Deerfield, USA, 10Takeda International - UK Branch, London, UK, 11Medical College of Wisconsin, Milwaukee, USA

P622: Child outcome in IBD pregnancy: early vs. late discontinuation of IFX therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Truta*1, T. Bayless1, J. Canner1, S. Bashar1

1Johns Hopkins University, Baltimore, USA

P623: Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Thomas*1, R. Cooney2, T. Iqbal2,3, S. Ghosh2,3, J. Ferguson3,4, G. Hirschfield5, P. Trivedi3,4,6,7

1University of Oxford, Translational Gastroenterology Unit, Oxford, UK, 2University Hospitals Birmingham, Birmingham, UK, 3National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Birmingham, UK, 4University Hospitals Birmingham, Liver Unit, Birmingham, UK, 5University Health Network, University of Toronto, Toronto Centre for Liver Disease, Toronto, Canada, 6University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, UK, 7University of Birmingham, Institute of Applied Health Research, Birmingham, UK

P624: Factors that may influence the development of anti-drug antibodies to adalimumab

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, I. Rauter2, L. Chen3, M. Gessner3, G. Fanjiang3

1Medical University of Vienna, Vienna, Austria, 2Amgen (Europe) GmbH, Rotkreuz, Switzerland, 3Amgen Inc., Thousand Oaks, USA

P625: Head-to-head comparison of three stool calprotectin tests for home use

ECCO '19 Copenhagen

Year: 2019
Authors:

S-M. Haisma*1, A. Galaurchi2, S. Almahwzi2, J. Adekanmi Balogun2, A. Muller Kobold3, P. van Rheenen1

1University Medical Center Groningen, Paediatric Gastroenterology, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University Medical Center Groningen, Laboratory Medicine, Groningen, The Netherlands

P626: Higher discontinuation rates of anti-TNF therapy in elderly IBD patients compared with a younger age group: results from a prospective registry

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Smits*1, M. de Jong1, N. den Broeder1, M. Russel2, T. Römkens3, R. West4, J. Jansen5, F. Hoentjen1

1Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Medisch Spectrum Twente, Gastroenterology and Hepatology, Enschede, The Netherlands, 3Jeroen Bosch Ziekenhuis, Gastroenterology and Hepatology, 's Hertogenbosch, The Netherlands, 4Franciscus Gasthuis and Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands

P627: Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn’s disease: Results from a population-based study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Y. Mak*1, W. Tang1, F. K. L. Chan1, W. K. Leung2, M. K. K. Li3, F. H. Lo4, C. K. M. Ng5, A. S. F. Sze6, C. M. Leung7, S. W. C. Tsang8, E. H. S. Shan9, K. H. Chan10, B. C. Y. Lam11, A. J. Hui12, W. H. Chow13, J. J. Y. Sung1, S. C. Ng1

1The Chinese University of Hong Kong, Medicine and Therapeutics, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 4United Christian Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 5Princess Margaret Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 6Queen Elizabeth Hospital, Medicine, Hong Kong, Hong Kong, 7Pamela Youde Nethersole Eastern Hospital, Medicine, Hong Kong, Hong Kong, 8Tseung Kwan O Hospital, Medicine, Hong Kong, Hong Kong, 9Caritas Medical Centre, Medicine and Geriatrics, Hong Kong, Hong Kong, 10North District Hospital, Medicine, Hong Kong, Hong Kong, 11Kwong Wah Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 12Alice Ho Miu Ling Nethersole Hospital, Medicine and Therapeutics, Hong Kong, Hong Kong, 13Yan Chai Hospital, Medicine, Hong Kong, Hong Kong

P628: Long-term outcomes with transmural healing vs. mucosal healing in Crohn’s disease: time for new treatment goals ?

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Castiglione1, N. Imperatore*1, A. Testa1, G. D. De Palma2, O. M. Nardone1, L. Pellegrini1, N. Caporaso1, A. Rispo1

1Gastroenterology, School of Medicine Federico II of Naples, Naples, Italy, 2Surgical Endoscopy, School of Medicine Federico II of Naples, Naples, Italy

P629: The initial trough concentration at 36 h after starting tacrolimus is important for the personalised medicine strategy in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Hida*1, K. Watanabe2, T. Miyazaki1, Y. Yokoyama2, M. Kawai1, T. Takagawa1, K. Kamikozuru1, T. Sato2, K. Fujimoto1, R. Koshiba1, K. Kojima1, S. Nakamura1

1Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nishinomiya, Hyogo, Japan, 2Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Hyogo, Japan

P630: A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Walmsley*1, A. McCombie2, M. Barclay2, N. Visesio1, C. Ho3, S. Brown4, K. Rosser5, S. Inns4, A. Gray6, H. Regenbrecht6, T. Langlotz6, M. Schultz6

1Waitemata District Health Board, Gastroenterology, Auckland, New Zealand, 2University of Otago, Medicine, Christchurch, New Zealand, 3Southern District Health Board, Gastroenterology, Dunedin, New Zealand, 4Hutt Valley District Health Board, Gastroenterology, Hutt, New Zealand, 5Canterbury District Health Board, Gastroenterology, Christchurch, New Zealand, 6University of Otago, Gastroenterology, Dunedun, New Zealand

P631: Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

P. S. Dulai*1, S. Singh1, N. Vande Casteele1, J. Meserve1, A. Winters2, S. Chablaney2, S. Aniwan3, P. Shashi4, G. Kochhar4, A. Weiss5, J. L. Koliani-Pace6, Y. Gao7, B. S. Boland1, J. T. Chang1, D. Faleck2, R. Hirten2, R. Ungaro2, D. Lukin5, K. Sultan7, D. Hudesman8, S. Chang8, M. Bohm9, S. Varma9, M. Fischer9, E. Shmidt10, A. Swaminath11, N. Gupta12, M. Rosario13, V. Jairath14, L. Guizzetti15, B. G. Feagan14, C. A. Siegel6, B. Shen4, S. Kane3, E. V. Loftus Jr3, W. J. Sandborn1, B. E. Sands2, J-F. Colombel2, K. Lasch13, C. Cao13

1University of California San Diego, La Jolla, CA, USA, 2Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3Mayo Clinic, Rochester, MN, USA, 4Cleveland Clinic Foundation, Cleveland, OH, USA, 5Montefiore Medical Center, New York, NY, USA, 6Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 7North Shore University Hospital, Manhasset, NY, USA, 8New York University (NYU), New York, NY, USA, 9Indiana University, Indianapolis, IN, United States, 10University of Minnesota, Minneapolis, MN, United States, 11Lenox Hill Hospital, New York, NY, United States, 12University of Mississippi, Jackson, MS, United States, 13Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, United States, 14University of Western Ontario, London, ON, Canada, 15Robarts Clinical Trials, London, ON, Canada

P632: Allogenic hPDMSCs gelatum in the treatment of perianal fistulas in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Tang*1, X. Wu1, X. Cao2, X. Gao1, P. Lan1

1The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Colorectal Surgery, Guangzhou, China, 2Tianjin Medical University General Hospital, Tianjin Medical University, Department of Gastroenterology and Hepatology, Tianjin, China

P633: Harmonisation of quality of care in an IBD centre impacts disease outcomes: importance of structure and process indicators

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Reinglas*1, S. Restellini2, L. Gonczi3, Z. Kurti3, S. Nene1, R. Kohen1, W. Afif1, T. Bessissow1, G. Wild1, E. Seidman1, A. Bitton1, P. Lakatos1

1McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary